DISTRIBUTION SERVICES AGREEMENTDistribution Services Agreement • March 2nd, 2015 • Kythera Biopharmaceuticals Inc • Pharmaceutical preparations • Delaware
This Distribution Services Agreement (“Agreement”) dated as of January 16, 2015 (“Effective Date”), is made by and between KYTHERA Biopharmaceuticals, Inc. (“Company”) and Besse Medical, a division of ASD Specialty Healthcare, Inc. (“Distributor”).
LICENSE AGREEMENT DATED AS OF FEBRUARY , 2015 BY AND BETWEEN THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA AND KYTHERA HOLDINGS, LTD. AND KYTHERA BIOPHARMACEUTICALS, INC.License Agreement • March 2nd, 2015 • Kythera Biopharmaceuticals Inc • Pharmaceutical preparations • Pennsylvania
This License Agreement (this “Agreement”) is dated as of February , 2015 (the “Effective Date”) by and among The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation (“Penn”), Kythera Holdings, Ltd., a Bermuda company (“Licensee”), and Kythera Biopharmaceuticals, Inc., a Delaware Corporation (“KBI”). Penn, Licensee and KBI (for purposes of Section 6.4.1) may be referred to herein as a “Party” or, collectively, as “Parties”.
Second Amendment to Manufacturing and Supply AgreementManufacturing and Supply Agreement • March 2nd, 2015 • Kythera Biopharmaceuticals Inc • Pharmaceutical preparations
This Second Amendment to the Manufacturing and Supply Agreement (this “Second Amendment”) is made as of October 17, 2014 (the “Effective Date of this Second Amendment”) by and between Pfizer, Inc., a corporation organized and existing under the laws of the State of Delaware, with offices at 235 E. 42nd Street, New York, NY 10017 (“Pfizer”) and Kythera Biopharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware, having an address of 30930 Russell Ranch Road, Third Floor, Westlake Village, CA 91362 (hereinafter “Customer”).
LICENSE AGREEMENTLicense Agreement • March 2nd, 2015 • Kythera Biopharmaceuticals Inc • Pharmaceutical preparations
This license agreement (the “Agreement”) is effective as of February __, 2015 (the “Effective Date”) by and among ACTELION PHARMACEUTICALS, LTD., a Swiss company located at Gewerbestrasse 16, CH-4123 Allschwil, Switzerland (“Actelion”), KYTHERA HOLDINGS, LTD., a Bermuda company located at Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda (“Kythera”), and KYTHERA BIOPHARMACEUTICALS, INC., a Delaware company located at 30930 Russell Ranch Road, 3rd Floor, Westlake Village, CA 91362, United States of America (“KBI”). Actelion, Kythera and KBI (but only with respect to section 12.5) are referred to individually as a “Party” and collectively as the “Parties”.
